AVXL Overview
Upcoming Projects (AVXL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AVXL)
-
A Second View: Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Tickers: AVXL, LLY, BIIB
Executed On: Aug 28, 2024 at 03:30 PM EDT -
Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Tickers: AVXL, LLY, BIIB
Executed On: Aug 06, 2024 at 10:30 AM EDT -
Examining the potential of Anavex' blarcamesine in Rett Syndrome with a focus on the recent data from the P3 AVATAR trial
Ticker: AVXL
Executed On: Aug 16, 2022 at 10:00 AM EDT -
A look at ANAVEX 2-73 (blarcamesine) in patients with Parkinson's and Alzheimer's Disease
Ticker: AVXL
Executed On: Jul 18, 2022 at 09:00 AM EDT
Expired Projects (AVXL)
-
Getting an informed look on the newly released phase 2b/3 data of oral ANAVEX 2-73 (blarcamesine) for early Alzheimer's disease.
Ticker: AVXL
Execute By: Nov 30, 2022 -
Examining Anavex’s lead drug candidate, 2-73 (blarcamesine) for central nervous system diseases
Ticker: AVXL
Execute By: Dec 23, 2020 -
Evaluating Anavex's (AVXL) 2-73 After News of Positive Response in Alzheimer's Patients Sends Stock Upwards
Ticker: AVXL
Execute By: Jun 03, 2016
Upcoming & Overdue Catalysts (AVXL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AVXL)
-
Anavex (AVXL) Presents Preclinical Data on ANAVEX 2-73 in a Classic Animal Model of Parkinson's Disease at World Parkinson Congress 2016
Ticker: AVXL
Occurred on: Sep 22, 2016 -
Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
Ticker: AVXL
Occurred on: Jul 24, 2016 -
Anavex's (AVXL) 3-71 for Frontotemporal Dementia Granted Orphan Drug Designation by FDA
Ticker: AVXL
Occurred on: Apr 08, 2016 -
Anavex (AVXL) Presents Preclinical Data on 3-71 for Alzheimer's Disease
Ticker: AVXL
Occurred on: Mar 14, 2016 -
Anavex (AVXL) Announces Two-Year Extension to Phase 2a Dose-Response Analysis of 2-73 in Alzheimer's Disease
Ticker: AVXL
Occurred on: Mar 10, 2016
Strategic Initiatives (AVXL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
